QDIS Blog

While Medimmune has in the past rejected merger talks, one of its largest shareholders is urging the board to reconsider. David Katz, president of Matrix Asset Advisors think that Medimmune should sell out. Given the current environment, it is likely they could get a great deal for their assets, but this basically says there is no confidence in the current management to build the company further for the future.

A Buyer For MedImmune?

I kind of agree with this assessment, while Medimmune has some good products such as FluMist and Synagis for treatment of infections in infants, they don’t seem to get the respect of the markets. While it may be worth more than the current stock price, I don’t think that David Katz figure of being worth $45 is quite realistic over the current price of $33. Look for Medimmune to investigate potential buyers but that field of large pharma is pretty small with Pfizer and GlaxoSmithKline being the primary players. Johnson and Johnson is less likely in my opinion and I seriously doubt Merck would consider this sort of acquisition now.

Technorati Tags: pharma M&A, pharmaceutical deals, Medimmune

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |